Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Enterprise Value (EV)
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Net Profit Margin since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Current ratio | ||||||
| Quick ratio | ||||||
| Cash ratio |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The liquidity position of the company demonstrates a generally improving trend from 2021 through 2024, with a slight moderation in 2025. All three liquidity ratios – current, quick, and cash – exhibited increases over the initial period examined, suggesting a strengthening ability to meet short-term obligations. The year 2025 shows a slight pullback from the peak liquidity achieved in 2024, but levels remain above those observed in earlier years.
- Current Ratio
- The current ratio increased steadily from 1.27 in 2021 to 1.60 in 2024, indicating a growing capacity to cover current liabilities with current assets. A slight decrease to 1.55 in 2025 suggests a moderate reduction in this capacity, though the ratio remains healthy. This indicates the company’s short-term financial health improved and remains solid.
- Quick Ratio
- The quick ratio followed a similar pattern to the current ratio, rising from 0.95 in 2021 to 1.20 in 2024. This improvement suggests an increasing ability to meet short-term obligations with the most liquid assets, excluding inventory. The ratio decreased to 1.06 in 2025, but still represents an improvement over the 2021 and 2022 levels. This indicates a strengthening of the company’s ability to pay off current liabilities without relying on the sale of inventory.
- Cash Ratio
- The cash ratio demonstrated the most substantial proportional increase, moving from 0.56 in 2021 to 0.83 in 2024. This signifies a considerable improvement in the company’s ability to cover immediate liabilities with cash and cash equivalents. A decrease to 0.65 in 2025 indicates a slight reduction in this immediate coverage, but the ratio remains higher than in the earlier years of the period. This suggests an increased focus on maintaining a strong cash position.
Overall, the trends in these liquidity ratios suggest a strengthening short-term financial position between 2021 and 2024, followed by a slight moderation in 2025. The company appears well-positioned to meet its short-term obligations, with a growing reliance on highly liquid assets as evidenced by the cash ratio trend.
Current Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Current ratio1 | ||||||
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Current Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Current Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The current ratio exhibited an overall increasing trend between December 31, 2021, and December 31, 2024, followed by a slight decrease in the most recent period. This indicates a generally improving ability to cover short-term obligations with short-term assets over the analyzed timeframe.
- Current Ratio Trend
- The current ratio began at 1.27 in 2021 and increased to 1.29 in 2022, representing a modest improvement. A more substantial increase was observed between 2022 and 2023, with the ratio reaching 1.43. This upward momentum continued into 2024, with the ratio peaking at 1.60. However, in 2025, the current ratio decreased slightly to 1.55, though it remained above the levels observed in 2021 and 2022.
The consistent rise in the current ratio from 2021 to 2024 suggests strengthening short-term financial health. The slight decline in 2025 does not necessarily indicate a cause for concern, but warrants further investigation into the composition of current assets and liabilities to understand the drivers of this change. The values consistently above 1.0 suggest the entity possesses more current assets than current liabilities throughout the period.
- Underlying Components
- Current assets increased from US$14,772 million in 2021 to US$19,173 million in 2024, contributing to the improved ratio. While current liabilities also increased, the growth in current assets outpaced the growth in current liabilities during this period. The decrease in the current ratio in 2025 is attributable to a combination of a decrease in current assets and a continued increase in current liabilities.
Overall, the current ratio demonstrates a positive trajectory with a minor pullback in the latest year. Continued monitoring of this ratio, alongside its underlying components, is recommended to assess the sustainability of this trend and potential impacts on short-term liquidity.
Quick Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and cash equivalents | ||||||
| Short-term marketable debt securities | ||||||
| Accounts receivable, net | ||||||
| Total quick assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Quick ratio1 | ||||||
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Quick Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Quick Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quick ratio exhibited a generally improving trend over the observed period, though with some fluctuation. Initial values indicated a position where quick assets were slightly less than current liabilities, but this position strengthened over time.
- Quick Ratio Trend
- The quick ratio began at 0.95 in 2021, indicating that the entity held 95 cents of quick assets for every dollar of current liabilities. A slight increase was observed in 2022, reaching 0.99. This upward movement continued into 2023, with the ratio rising to 1.06, signifying the entity’s ability to cover current liabilities with quick assets. The most substantial increase occurred between 2023 and 2024, with the quick ratio reaching 1.20. This suggests a considerable improvement in short-term liquidity. However, the ratio decreased slightly in 2025, settling at 1.06, remaining above the 2023 level but below the peak in 2024.
The increase in the quick ratio from 2021 to 2024 suggests improved management of liquid assets relative to short-term obligations. The slight decline in 2025 warrants further investigation to determine if it represents a temporary fluctuation or the beginning of a new trend. Overall, the quick ratio values indicate a strengthening short-term financial position during the majority of the analyzed period.
- Supporting Financial Items
- Total quick assets increased from US$11,013 million in 2021 to US$14,411 million in 2024, contributing to the improved quick ratio. While quick assets decreased to US$12,545 million in 2025, they remained above the 2021-2023 levels. Current liabilities remained relatively stable between 2021 and 2023, fluctuating between US$11,237 million and US$11,610 million, before increasing to US$12,004 million in 2024 and decreasing slightly to US$11,813 million in 2025. The combination of increasing quick assets and relatively stable current liabilities drove the positive trend in the quick ratio.
Cash Ratio
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and cash equivalents | ||||||
| Short-term marketable debt securities | ||||||
| Total cash assets | ||||||
| Current liabilities | ||||||
| Liquidity Ratio | ||||||
| Cash ratio1 | ||||||
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Cash Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Cash Ratio, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio exhibited a generally positive trend over the five-year period, though with some fluctuation. Initial values were relatively stable before a notable increase, followed by a slight decline in the most recent year observed.
- Cash Ratio Trend
- The cash ratio began at 0.56 in 2021 and increased to 0.57 in 2022, indicating a minimal change in the company’s ability to cover current liabilities with only cash and cash equivalents. A more substantial increase was observed in 2023, with the ratio reaching 0.64. This suggests an improved immediate liquidity position. The ratio peaked at 0.83 in 2024, representing the strongest ability to meet short-term obligations using only cash assets within the observed timeframe. However, the ratio decreased to 0.65 in 2025, indicating a slight weakening of this immediate liquidity strength, though remaining above the levels seen in 2021 and 2022.
- Underlying Components
- Total cash assets generally increased over the period, moving from US$6,520 million in 2021 to US$7,264 million in 2023, then peaking at US$9,991 million in 2024 before decreasing to US$7,632 million in 2025. Current liabilities remained relatively stable between US$11,237 million and US$12,004 million throughout the period, with a slight upward trend in 2024. The fluctuations in the cash ratio largely correspond with the changes in total cash assets, as current liabilities remained comparatively consistent.
The increase in the cash ratio through 2024 suggests a strengthening of the company’s short-term liquidity. The subsequent decrease in 2025, while still representing a healthy ratio, warrants further investigation to understand the reasons behind the reduction in cash holdings and its potential impact on future short-term obligations.